Search results for "PHASE"

showing 10 items of 6344 documents

Biological parameters in breast cancer.

1996

AdultAged 80 and overCA15-3Oncologymedicine.medical_specialtyPloidiesbusiness.industryGeneral NeuroscienceBreast NeoplasmsDNA NeoplasmMiddle AgedPrognosismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyS PhaseBreast cancerHistory and Philosophy of ScienceEvaluation Studies as TopicInternal medicinemedicineHumansFemalebusinessAged
researchProduct

Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters an…

1995

Background. The traditional factors of locally advanced laryngeal squamous cell carcinoma (LSCC) have limited predictive value for the identification of high risk patients. Therefore, it is extremely important to define prognostic factors that identify the more aggressive types. Reliable and reproducible prognostic indicators are being investigated to help clinicians identify high risk groups and address more rational treatment. Methods. Flow cytometric DNA ploidy and S‐phase fraction (SPF) measurements were performed on frozen tumor tissues from a consecutive series of 71 patients with Stage III and IV LSCC. Lysosomal cathepsin B and L activity levels were determined biochemically in match…

AdultAged 80 and overMaleCathepsin LDNA NeoplasmMiddle AgedAneuploidyFlow CytometryPrognosisCathepsinsCathepsin BS PhaseCysteine EndopeptidasesEndopeptidasesHumansFemalecathepsin B and L DNA ploidy flow cytometry laryngeal squamous cell carcinoma S‐phase fractionLysosomesLaryngeal NeoplasmsAgedCancer
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Bioelectrical characteristics of type 1 and type 2 diabetic subjects with reference to body water compartments.

1998

Since bioelectrical characteristics correspond well to body water compartments, this study investigated bioelectrical differences between type 1 and type 2 diabetic subjects that could reflect differences in body water compartments. We investigated cross-sectionally 612 adult subjects, classified into 10 groups according to sex and disease (control, obese normal glucose tolerant, non-obese type 2 diabetes, obese type 2 diabetes, type 1 diabetes). Resistance (R), reactance (Xc) and phase angle (PA) were measured (800 microA - 50 kHz alternating current). The bioelectrical vector was obtained by plotting R and Xc normalized for height (ht), it is easily identified on the basis of the length (…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismBody waterType 2 diabetesEndocrinologyBody WaterInternal medicineDiabetes mellitusInternal MedicineElectric ImpedanceMedicineHumansAgedType 1 diabetesbusiness.industryPhase angleGeneral MedicineBody Fluid CompartmentsFastingAnthropometryMiddle Agedmedicine.diseaseObesityEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 1Diabetes Mellitus Type 2FemaleAnalysis of variancebusinessActa diabetologica
researchProduct

Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.

1991

A phase I clinical trial was conducted with recombinant human tumour necrosis factor alpha (rhTNF-alpha) in 62 patients with advanced malignancy refractory to previous standard therapy. rhTNF-alpha was given as a 30 min infusion twice a day at 6 h intervals. A total of 10 different dose levels was escalated in cohorts of 6 patients ranging from 2.5 to 200 micrograms/m2 twice a day for 5 days every second week for a total of 8 weeks followed by a 4-week observation period. Major side-effects of TNF-alpha therapy, seen in almost all patients studied, were fever and chills. As dose-limiting side-effects hypotension and liver toxicity were recorded in 4 of 5 patients treated with 200 micrograms…

AdultBlood PlateletsMalemedicine.medical_specialtyNecrosisAdolescentFeverPhases of clinical researchBlood PressureMalignancyGastroenterologyHemoglobinsLeukocyte CountPharmacokineticsRefractoryInternal medicineNeoplasmsmedicineLeukocytesHumansAgedbiologyDose-Response Relationship Drugbusiness.industryPlatelet CountTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologybiology.proteinDrug EvaluationTumor necrosis factor alphaChillsFemaleAntibodymedicine.symptombusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…

2014

Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…

AdultCancer ResearchPhases of clinical researchBreast NeoplasmsPharmacologyAntibodies Monoclonal HumanizedArticleReceptor IGF Type 1Ridaforolimuschemistry.chemical_compoundBreast cancerIn vivoAntineoplastic Combined Chemotherapy ProtocolsMedicineAnimalsHumansPI3K/AKT/mTOR pathwayInsulin-like growth factor 1 receptorAgedSirolimusDalotuzumabbusiness.industryTOR Serine-Threonine KinasesAntibodies MonoclonalReceptors SomatomedinMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysOncologychemistryMonoclonalbusinessSignal TransductionClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

New spectrophotometric procedure for determining cefotaxime based on derivatization with 1,2-naphthoquinone-4-sulphonate into solid-phase extraction …

1998

Cefotaxime was derivatised with 1,2-naphthoquinone-4-sulphonate (NQS), extracted into solid-phase cartridges (C18) and detected using a UV-visible detection system. Optimum conditions for this new procedure were: hydrogencarbonate-carbonate buffer, pH 10.5, 5-min reaction time at 25 degrees C and an NQS concentration of 7.1x10(-3) mol l(-1). The accuracy and the precision of the liquid-solid procedure were tested. The procedure was used to measure cefotaxime in pharmaceutical and urine samples. The results obtained were contrasted with those reported for a HPLC method for urine samples. The generalized H-point standard additions method was used to measure cefotaxime in urine samples.

AdultCefotaximeChromatographyNQSGeneral ChemistryUrineCefotaximeHigh-performance liquid chromatographySensitivity and SpecificityCephalosporinschemistry.chemical_compoundchemistryPharmaceutical PreparationsSpectrophotometryStandard additionmedicineHumansIndicators and ReagentsSolid phase extractionDerivatizationChromatography High Pressure LiquidAntibacterial agentmedicine.drugNaphthoquinonesJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Coping with an acute psychosocial challenge: behavioral and physiological responses in young women.

2014

Despite the relevance of behavior in understanding individual differences in the strategies used to cope with stressors, behavioral responses and their relationships with psychobiological changes have received little attention. In this study on young women, we aimed at analyzing the associations among different components of the stress response and behavioral coping using a laboratory psychosocial stressor. The Ethological Coding System for Interviews, as well as neuroendocrine, autonomic and mood parameters, were used to measure the stress response in 34 young women (17 free-cycling women in their early follicular phase and 17 oral contraceptive users) subjected to the Trier Social Stress …

AdultCoping (psychology)endocrine systemAdolescentHydrocortisonePhysiologyCardiologyPsychological StressEye contactlcsh:MedicineAnxietyHeart RateAdaptation PsychologicalHuman PerformanceMedicine and Health SciencesTrier social stress testmedicinePsychologyHumansSalivalcsh:ScienceMenstrual CyclePersonality TraitsSocial stressBehaviorAnalysis of VarianceCross-Over StudiesMultidisciplinaryEndocrine PhysiologyStressorlcsh:RBiology and Life SciencesAffectMoodFollicular PhaseAnxietyFemalelcsh:Qmedicine.symptomPsychologyPsychosocialStress PsychologicalResearch ArticleNeurosciencePersonalityClinical psychologyPLoS ONE
researchProduct

Quality-of-Life Priorities in Patients with Thyroid Cancer : a Multinational European Organisation for Research and Treatment of Cancer Phase I Study

2016

Item does not contain fulltext BACKGROUND: The objectives of this study were to determine quality of life (QoL) issues that are relevant to thyroid cancer patients cross-culturally, and to identify those with highest relevance to them in addition to the more general issues covered by the core European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30). METHODS: A systematic literature search provided a list of potentially relevant QoL issues to supplement the core questionnaire EORTC QLQ-C30, which is widely used in research and in care and addresses QoL issues relevant to all groups of cancer patients. A panel of experts revised this list, and thyroid cance…

AdultCross-Cultural ComparisonMalemedicine.medical_specialtyPathologyInternationalityEndocrinology Diabetes and MetabolismAlternative medicine030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeAdenocarcinoma FollicularMedicineHumansIn patientThyroid NeoplasmsVoluntary Health AgenciesThyroid cancerFatigueAgedNeoplasm StagingAged 80 and overbusiness.industryCancerRehabilitation VocationalMiddle Agedmedicine.diseaseCross-cultural studiesCombined Modality TherapyCarcinoma PapillaryhumanitiesPhase i studyCarcinoma NeuroendocrineEuropeMultinational corporationThyroid Cancer Papillary030220 oncology & carcinogenesisFamily medicineCarcinoma MedullaryQuality of LifeFemaleSelf ReportbusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]
researchProduct

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…

2009

Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…

AdultDiarrheaMalemedicine.medical_specialtyNeutropeniaTime FactorsEsophageal NeoplasmsCetuximabPhases of clinical researchKaplan-Meier EstimateAntibodies Monoclonal Humanizedmedicine.disease_causeGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalAgedCross-Over StudiesDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalNauseaHematologyMiddle AgedCombined Modality TherapySurvival AnalysisChemotherapy regimenSurgeryTreatment OutcomeOncologyEpidermoid carcinomaFluorouracilResponse Evaluation Criteria in Solid TumorsCarcinoma Squamous CellFemaleFluorouracilKRASCisplatinbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct